Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston CE marks Taxus Element

This article was originally published in Clinica

Executive Summary

Boston Scientific has CE marked its Taxus Element paclitaxel-eluting stent for sale in Europe. The "third-generation" device is made of a platinum chromium alloy which is stronger and more flexible than older alloys such as cobalt chromium, the company claims. The CE mark also specifically states that the stent can be used in diabetic patients. Boston (Natick, Massachusetts) plans to launch Taxus Element in the EU and other countries that recognise the CE mark next month, and expects US FDA approval to follow in mid-2011. The firm CE marked another stent that uses the same platinum chromium alloy, the everolimus-eluting Promus Element, last November (www.clinica.co.uk, 3 November 2009).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel